홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.0
  1. 홈
  2. /화합물

1,3-디프로필-8-(3-노라다만틸)크산틴

Rolofylline

HCID 11948288
새 노트새 반응견적 요청하기
인쇄 미리보기
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
136199-02-5
표준 SMILES
CCCn1c(=O)c2[nH]c(C34C[C@@H]5CC3C[C@@H](C5)C4)nc2n(CCC)c1=O
InChIKey
PJBFVWGQFLYWCB-QUYAXPHCSA-N
분자식
C20H28N4O2
평균 분자량
356.5 g/mol
단동위원소 질량
356.22122615

개요

Rolofylline is under clinical development by pharmaceutical company NovaCardia for the treatment of congestive heart failure.

이름 및 식별자

우선 이름
Rolofylline
IUPAC
1,3-dipropyl-8-[(1R,5S)-3-tricyclo[3.3.1.03,7]nonanyl]-7H-purine-2,6-dione
현지명
1,3-디프로필-8-(3-노라다만틸)크산틴
영어명
1,3-dipropyl-8-(3-noradamantyl)xanthine
분자식
C20H28N4O2
분자량
356.46

이름 및 동의어

1,3-DnaxKW-3902KW 39027805S5HIHX1,3-Dipropyl-8-(3-noradamantyl)xanthine8-(3-Noradamantyl)-1,3-dipropylxanthine8-(Noradamantan-3-yl)-1,3-dipropylxanthineMK-7418Rolofyllina1,3-DIPROPYL-8-(TRICYCLO(3.3.1.0(SUP 3,7))NON-3-YL)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE3,7-DIHYDRO-1,3-DIPROPYL-8-(3-TRICYCLO(3.3.1.0(SUP 3,7))NONYL)-1H-PURINE-2,6-DIONErolofyllinum
이름 더 보기
1,3-디프로필-8-(3-노라다만틸)크산틴HMR-4902KW-3902 >=98% (HPLC)Rolofylline, 10 mM in DMSOKW-3902|||MK-7418|||KF-153728-(Hexahydro-2,5-methano-pentalen-3a-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione8-(Hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione
MK7418RefChem:8836891,3-dipropyl-8-((1R,5S)-tricyclo(3.3.1.0^(3,7))nonan-3-yl)-2,3,6,7-tetrahydro-1H-purine-2,6-dione663-792-2136199-02-5KW3902RolofyllineRolofylline [USAN]

물성

구조 계산 물성

XLogP
4.9
극성 표면적
69.3 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
3
회전 가능 결합 수
5
무거운 원자 수
26
형식 전하
0
복잡도
609

실험 및 물리화학적 성질

DrugsPharmaceuticals -> Listed in ZINC15

물리화학적 성질

끓는 점
578 · 578.0±42.0 °C(Predicted)
밀도
1.262 · 1.262±0.06 g/cm3(Predicted)
저장 조건
2 · 2-8°C
용해도
20 mg/mL · DMSO: 가용성20mg/mL
물리적 상태
고체
산도 계수 (pKa)
9.23 · 9.23±0.70(Predicted)
색상
White to off-white
InChI
1S/C20H28N4O2/c1-3-5-23-16-15(17(25)24(6-4-2)19(23)26)21-18(22-16)20-10-12-7-13(11-20)9-14(20)8-12/h12-14H,3-11H2,1-2H3,(H,21,22)/t12-,13+,14-,20-
InChIKey
PJBFVWGQFLYWCB-OYEQCZOJSA-N
SMILES
CCCN1C(=O)N(CCC)c2[nH]c(nc2C1=O)[C@]34C[C@H]5C[C@H](C[C@@H]3C5)C4

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Danger

H370 (47.3%): Causes damage to organs [Danger Specific target organ toxicity, single exposure]

P260, P264, P270, P273, P308+P316, P319, P321, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 74 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Hazard Classes and CategoriesSTOT SE 1 (47.3%)

안전 데이터

wgk
3
Hazard Classifications
Aquatic Chronic 4
스토리지 클래스
11 - Combustible Solids

화학 및 산업

약리 정보

Mechanism of Action · 1건

Rolofylline is an adenosine A1-receptor antagonist. Plasma adenosine levels are elevated in patients with heart failure and adenosine A1 receptors in the kidney mediate vasoconstriction of afferent arterioles, reabsorption of sodium and water in proximal tubules, and tubuloglomerular feedback in the juxtaglomerular apparatus. Accordingly, inhibition of these receptors would be expected to increase renal blood flow and enhance diuresis. The effects of Rolofylline on renal function are consistent with those obtained with another adenosine A1-receptor antagonist in both experimental and human heart failure.

MeSH Pharmacological ClassificationAgents that promote the excretion of urine through their effects on kidney function.
응용 분야 · 2건

개요KW 3902 is an antagonist of the adenosine A1 receptor (Ki = 0.19 nM). It displays 890-fold selectivity for A1 receptors over A2A receptors and has no activity at A3 receptors. KW 3902 less potently inhibits human organic anion transporter 1 (OAT1; Ki = 7.82 μM). KW 3902 exhibits renal protective effects during hypoxemia in rabbits.

용도KW 3902 is an adenosine A1-receptor antagonist, which has recently been shown to alleviate axonopathy caused by human Tau ΔK280. KW 3902 can be considered for the development of a treatment towards hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases.

관련 반응

0건
반응 기록 만들기

현재 필터 조건에 해당하는 반응 기록이 없습니다.

화합물 노트

불러오는 중…

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
더보기
새 노트새 반응견적 요청하기

데이터베이스 식별자

CAS
136199-02-5
PubChem CID
11948288
ChEMBL
CHEMBL52333
UNII
7805S5HIHX
EC Number
663-792-2